Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes. Kang YM, Nauck MA. Lancet 2026;408:1526-1527.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang YM, Nauck MA. Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes. Lancet 2026;408:1526-1527.
PMID: 42880294